MAP1LC3B

Across TCGA pan-cancer cohorts, MAP1LC3B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP1LC3B data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAP1LC3B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAP1LC3B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC, LSCC, and UCEC are the cancer types where MAP1LC3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.750	0.945	.002	12	view →
LSCC	DFS	Median	All	0.506	0.916	.016	7	view →
UCEC	DFS	Median	II,III,IV	0.602	1.000	.049	4	view →
GBM	OS	Quartile	All	0.551	0.333	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAP1LC3B–HNSC (OS)

Open the HNSC breakdown →